Invicorp autoinjection of vasoactive intestinal polypeptide data

SNTKY announced that a study in 70 patients showed a successful achievement of erections in 47. Phase III data has been submitted for marketing approval in the U.K.

The trial was in consecutive patients at a clinic, who had failed prior therapy with prostaglandin E1 (alprostadil), and papaverine plus phentolamine. Clinical supervision of the Invicorp system was followed by home use. None of the patients had adverse events other than facial flush in 37 of the men. ...